search
Back to results

Tubal Flushing Using Water Soluble Media for Unexplained Infertility

Primary Purpose

Infertility

Status
Unknown status
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Tubal flushing by Urografin®
Diclofenac
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • infertility for one year
  • Normal semen analysis
  • Normal ovulation

Exclusion Criteria:

  • Allergy to Iodine
  • Metformin therapy
  • Tubal block

Sites / Locations

  • BeniSuef University hospitalsRecruiting
  • Cairo University HospitalsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Tubal flushing with Urografin®

Control group

Arm Description

Women will have HSG using water soluble media

Women will not receive any intervention

Outcomes

Primary Outcome Measures

Pregnancy
Pregnancy will be defined as the presence of an intrauterine sac by vaginal ultrasound

Secondary Outcome Measures

Full Information

First Posted
April 24, 2015
Last Updated
January 20, 2017
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT02433418
Brief Title
Tubal Flushing Using Water Soluble Media for Unexplained Infertility
Official Title
Tubal Flushing Using Water Soluble Media for Unexplained Infertility: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
300 women with unexplained infertility will be randomly divided into 2 equal groups: Group 1 will be offered tubal flushing with water soluble media through hysterosalpingography (HSG) and group 2 will receive no intervention
Detailed Description
The potential therapeutic effect of diagnostic tubal patency testing has been debated for over 40 years. Tubal flushing might involve water- or oil-soluble media. Current practice usually involves water-soluble media when tubal flushing is performed at laparoscopy. A systematic review showed a significant increase in pregnancy rates with tubal flushing using oil-soluble contrast media when compared with no treatment. Tubal flushing with oil soluble contrast media was associated with an increase in the odds of live birth when compared with tubal flushing with water-soluble media. There were no trials assessing tubal flushing with water-soluble media versus no treatment. The potential consequences of extravasations of oil-soluble contrast media into the pelvic cavity and fallopian tubes may be associated with anaphylaxis and lipogranuloma. It has been reported that Further randomised controlled trials are needed to evaluate the potentially therapeutic effects of tubal flushing with water-soluble media. All patients attending the subfertility clinic with infertility, normal semen analysis and evidence of ovulation will be invited to participate in the study. The nature of the study and its expected values will be explained and only women who provide written consents will be included in the study. Three hundred women will be divided into 2 equal groups using computer generated random numbers: Group 1 will have tubal flushing with HSG using water soluble media and group 2 will be the control group receiving no intervention. Women undergoing HSG will be given 50 mg of diclofenac (Voltaren® Novartis) 1 hour before the procedure. The HSG will be performed in the same room, on the same table and with the same technique to maintain consistency and limit confounding variables. The HSG procedure will performed in a lithotomy position. A sterile metal speculum was used to visualize the uterine cervix. Antiseptic solution will be used to wash the vagina and cervix. A single-toothed tenaculum will be placed on the anterior lip of the cervix. A metal cannula will be gently inserted into the external cervical os, the cannula and tenaculum will be secured together, and the speculum will be removed. Gentle traction will be placed on the tenaculum, and 15 mL to 20 mL of water-soluble media (Sodium Amidotrizoate; urografin®, Bayer, Germany) will be instilled slowly via the cannula to prevent pain while the necessary images were obtained. After the procedure, the instruments will be removed and the patient will be observed for 30 minutes. Women will be followed up monthly for up to 1 year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tubal flushing with Urografin®
Arm Type
Active Comparator
Arm Description
Women will have HSG using water soluble media
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Women will not receive any intervention
Intervention Type
Procedure
Intervention Name(s)
Tubal flushing by Urografin®
Intervention Description
Women will have tubal flushing through HSG using water soluble media (Urographin ®)
Intervention Type
Drug
Intervention Name(s)
Diclofenac
Intervention Description
Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
Primary Outcome Measure Information:
Title
Pregnancy
Description
Pregnancy will be defined as the presence of an intrauterine sac by vaginal ultrasound
Time Frame
Monthly, up to 12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: infertility for one year Normal semen analysis Normal ovulation Exclusion Criteria: Allergy to Iodine Metformin therapy Tubal block
Facility Information:
Facility Name
BeniSuef University hospitals
City
BeniSuef
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nesreen AA Shehata, MD
Phone
+2001227866337
Email
nesoomar@yahoo.com
Facility Name
Cairo University Hospitals
City
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
AbdelGany MA Hassan, MRCOG, MD
Phone
00217801604
Email
abdelgany2@gmail.com
First Name & Middle Initial & Last Name & Degree
AbdelGany MA Hassan, MRCOG, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
12517654
Citation
Steiner AZ, Meyer WR, Clark RL, Hartmann KE. Oil-soluble contrast during hysterosalpingography in women with proven tubal patency. Obstet Gynecol. 2003 Jan;101(1):109-13. doi: 10.1016/s0029-7844(02)02390-6.
Results Reference
background
PubMed Identifier
10644101
Citation
Spring DB, Barkan HE, Pruyn SC. Potential therapeutic effects of contrast materials in hysterosalpingography: a prospective randomized clinical trial. Kaiser Permanente Infertility Work Group. Radiology. 2000 Jan;214(1):53-7. doi: 10.1148/radiology.214.1.r00ja2353.
Results Reference
background
PubMed Identifier
17636730
Citation
Luttjeboer F, Harada T, Hughes E, Johnson N, Lilford R, Mol BW. Tubal flushing for subfertility. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003718. doi: 10.1002/14651858.CD003718.pub3.
Results Reference
background
PubMed Identifier
33053612
Citation
Wang R, Watson A, Johnson N, Cheung K, Fitzgerald C, Mol BWJ, Mohiyiddeen L. Tubal flushing for subfertility. Cochrane Database Syst Rev. 2020 Oct 15;10(10):CD003718. doi: 10.1002/14651858.CD003718.pub5.
Results Reference
derived

Learn more about this trial

Tubal Flushing Using Water Soluble Media for Unexplained Infertility

We'll reach out to this number within 24 hrs